2021 • KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)–pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)—New data after an additional 1 year of follow-up.

  • Popularity: This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
  • Influence: This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
  • Citation Count: This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
  • Impulse: This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.